We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New COVID-19 Test to Scan Saliva or Nasal Swabs Using Specialized Probes for Detecting SARS-CoV-2 RNA Sequences

By LabMedica International staff writers
Posted on 25 Feb 2021
A newly-developed test has the ability to analyze and detect the many subtle changes that can occur in the SARS-CoV-2 viral genome - so-called variants, such as those first identified in the UK and South Africa.

The technique, being developed by researchers at Johns Hopkins Medicine (Baltimore, MD, USA), scans biological specimens, including saliva or nasal swabs, using specialized DNA probes that sift through a complex “forest” of RNA sequences. More...
The probes can detect specific RNA sequences of viruses and other disease-causing pathogens. The team has named their test “cRASL-seq” (pronounced krazzle-seek) which stands for capture RNA-mediated oligonucleotide annealing selection and ligation with next generation DNA sequencing.

The cRASL-seq test uses DNA sequencing instruments, which are able to analyze hundreds to thousands of samples at a time. Each test can detect not only SARS-CoV-2, but many other infectious organisms, say the scientists. Additionally, cRASL-seq skips a step that is required with most of the currently available tests for SARS-CoV-2. Most tests rely on RNA purification kits, which have often been in short supply, hampering efforts to test large swaths of people. The new test does not rely on such purification kits. Rather, it uses specific probes and magnetic beads to capture target RNA at the same time that the detection probes are binding to the viral RNA. The team is continuing to improve the cRASL-seq technology, expanding the test to detect additional organisms and new SARS-CoV-2 variants as they emerge.

“Detecting and tracking the genetic changes associated with these new strains is an enormous priority,” says Ben Larman, Ph.D., assistant professor of pathology and director of the Laboratory of Precision Immunology within the Institute for Cell Engineering at the Johns Hopkins University School of Medicine. “Sequencing instruments are ubiquitous now. This type of laboratory test could be adopted by centers all over the world to detect emerging pathogens and even resistance elements associated with bacterial and fungal infections.”

Related Links:
Johns Hopkins Medicine


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: The addition of Biocare’s complementary IHC antibody, reagent and instrument portfolio enhances Agilent’s immunohistochemistry offering (Photo courtesy of Biocare Medical)

Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical

Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.